Thursday, March 16, 2023
Prelude Therapeutics Incorporated announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in combination with BeiGene’s BTK inhibitor, zanubrutinib, in haematologic malignancies.
Under terms of the clinical trial collaboration agreement, BeiGene will provide zanubrutinib to Prelude, and Prelude will retain all global operational, development and commercialisation rights and responsibilities for PRT2527.
Zanubrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical programme as a monotherapy and in combination with other therapies to treat various B-cell malignancies. Zanubrutinib (BRUKINSA®) is approved in over 60 markets, including the United States, China, the European Union, Great Britain, Canada, Australia, South Korea, Iceland, Norway and Switzerland.
PRT2527 was designed to be a potent and selective Cyclin-dependant kinase 9, or CDK9, inhibitor. In preclinical studies, PRT2527 has shown to reduce MCL1 and MYC protein levels and was highly active in preclinical models at well-tolerated doses. PRT2527 has demonstrated high potency and kinase selectivity which may offer improved efficacy and safety compared to less selective CDK9 inhibitors, allowing for rapid development in combinations. PRT2527 is currently being studied as monotherapy in a Phase 1 dose-escalation study in advanced solid tumours, as well as in relapsed/refractory haematologic malignancies.
